Navigation Links
Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
Date:3/28/2013

ty of adult diseases.

The positive clinical results of a phase 2A trial of EPI-743 in children with Leigh syndrome were recently reported in Molecular Genetics and Metabolism (EPI-743 reverses the progression of the pediatric mitochondrial disease—Genetically defined Leigh Syndrome 107 (2012) 383-388). Separate manuscripts detailing EPI-743 treatment effect on CNS and systemic glutathione biomarker levels are also reported in Molecular Genetics and Metabolism (Brain uptake of Tc99m-HMPAO correlates with clinical response to the novel redox modulating agent EPI-743 in patients with mitochondrial disease 107 (2012) 690-699; Glutathione: A redox signature in monitoring EPI-743 therapy in children with mitochondrial encephalomyopathies (2013), in press). 

Edison Pharmaceuticals
Edison Pharmaceuticals is a specialty pharmaceutical company dedicated to developing treatments for children and adults with orphan mitochondrial diseases. EPI-743 is in phase 2 clinical development for the treatment of inherited respiratory chain disorders. Double-blind placebo-controlled trials are ongoing for the following indications: Leigh syndrome, Friedreich's ataxia, Cobalamin C defect, and Undiagnosed Disorders of Oxidation-Reduction. 

Dainippon Sumitomo Pharma Co., Ltd.
Dainippon Sumitomo Pharma Co., Ltd. (DSP) is a multi-billion dollar, top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical products. DSP aims to produce innovative pharmaceutical products in the psychiatry and neurology, which is designated as a key therapeutic area, as well as oncology. DSP has more than 7,000 employees worldwide. Additional information about DSP is available through its corporate website at www.ds-pharma.com.


'/>"/>
SOURCE Edison Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
2. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
3. Edison Pharmaceuticals Closes $20M Series F Financing
4. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
5. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
6. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
7. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
8. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
9. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
10. Harwood Feffer LLP Announces Investigation of Spectrum Pharmaceuticals, Inc.
11. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Cynosure, Inc. (Nasdaq: CYNO ... treatment systems for high-volume applications, today reported financial results ... 2014 financial results incorporate the acquisition of Palomar Medical ... Second-Quarter 2014 Financial Highlights ... , Non-GAAP net income of $7.1 million, or ...
(Date:7/29/2014)... 2014   What:   ... present data from a Phase I clinical trial of ... stop Parkinson,s disease progression. The Michael J. Fox Foundation ... will discuss the impact of the results for patients ... July 31, 2014         ...
(Date:7/29/2014)... , July 29, 2014  Drug development for ... rising incidence rates and the intense need for ... vaccine. Change is underway as the market moves ... highly effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is the first ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... previously announced underwritten public offering of 16,300,000 shares of ... per share to the public. The gross proceeds to ... $130,400,000, before deducting underwriting discounts and commissions, and other ...
... 26, 2011 American Scientific Resources, Inc. (OTCQB: ASFX) ... and Sanomedics International Holdings, Inc., and its affiliates, have ... United States District Court for the Southern District of ... judge, Hon. Ursula Ungaro, and the case has been ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3American Scientific Resources, Inc. Announces Dismissal of Sanomedics International Holdings, Inc. lawsuit 2
(Date:7/30/2014)... According to the Yeast Infection No More ... guide that will help candida sufferers get rid of their ... book uncovers to readers the truth about yeast infection and ... book, people will discover natural and safe remedies to relieve ... burning, and irritation of the vagina or vulva. , ...
(Date:7/30/2014)... 2014 The San Diego personal injury lawyers ... announcing that they are now offering free case reviews for ... asbestos exposure. , “Symptoms of asbestos exposure can take years ... 30 plus years ago may just now be suffering from ... Office of Melinda J. Helbock A.P.C. “We want people to ...
(Date:7/29/2014)... 30, 2014 VisitandCare.com today ... been added to the company’s exclusive network to help ... of joint efforts — as top fertility clinics in ... offer affordable, state-of-the-art, and successful IVF treatments. , The ... a comprehensive study by professionals at VisitandCare.com. The goal ...
(Date:7/29/2014)... Angeles, California (PRWEB) July 29, 2014 ... Education’ to senior communities with focus on Brain ... Aegis Living in Ventura. Brain Fitness Program Director ... lecture to Aegis Memory Care unit and the ... separate sessions. Aegis Life Enrichment Director Christy Rozsa ...
(Date:7/29/2014)... Hopkins researchers say they have discovered a chemical alteration ... that, if confirmed in larger studies, could give doctors ... risk of attempting suicide. , The discovery, described online ... that changes in a gene involved in the function ... significant role in turning what might otherwise be an ...
Breaking Medicine News(10 mins):Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3
... Bolling Air Force Base in Washington D.C., as well as a lecture ... ... Washington, D.C. (Vocus) July 2, 2008 -- The Drug Enforcement Administration ... Richard Nixon, who through an Executive Order established a single unified command ...
... QuadraBloc™, a new and improved version of AmWay's MagnaBloc. , ... ... a long-popular form of pain management, is now available in a ... ,"QuadraBloc has already been released in the United States, and will ...
... will be October 24-26, 2008 at the Catholic Institute in Toulouse, ... knowledge, ideas, applications and prospective issues in an interactive and collaborative ... http://www.ifats08.org for details. , ... Carmel, IN (PRWEB) ...
... using a combination of drugs targeting different parts of ... with severe lupus involving the kidneys, according to a ... Society of Nephrology (JASN). , "In our study, ... therapy for inducing complete remission of class V+IV lupus ...
... Clearance of Uniquely Integrated Meter/Pump System with ... and Compatible Software, WEST CHESTER, Pa., July ... its OneTouch(R) Ping(TM) Glucose Management System,by the U.S. ... the first,full-feature insulin pump that wirelessly communicates with ...
... of 300 human genomes in just over six months. The ... of genetic code that will be read by researchers worldwide, ... and disease. Scientists will be able to answer questions unthinkable ... be transformed. , The amount of data is remarkable: ...
Cached Medicine News:Health News:New MagnaBloc™ Product Available from Gradient Medical 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 3Health News:'Multi-target' immune therapy improves outcomes of severe lupus nephritis 2Health News:OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA 2Health News:OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA 3Health News:15 human genomes each week 2Health News:15 human genomes each week 3
... The new Guidant VASOVIEW® HemoPro™ ... deliver a new level of ... for both the saphenous vein ... cut-and-seal capability, it lets you ...
Patient Monitor...
...
... or antepartum GBS results can be available in ... revolutionary in vitro diagnostic test is the first ... in the clinical lab and near-patient by non-laboratory ... 24 hours a day, 365 days a year. ...
Medicine Products: